



PROGRAMME

- 9:30 – 9:45** **INTRODUCTION**
Dominique BAZY • President of Fondation ARC
Fabien CALVO • President of the International Clinical Research Committee of Fondation ARC
- 9:45 – 10:45** **TUMOUR STROMAL MICROENVIRONMENT**
Chaired by Anna BRICHKINA • Marburg, Germany
and Enrico GIRAUDO • Candiolo, Italy
- 9:45 Hyper-glycosylation in Pancreatic cancer: a driving force for ECM and tissue remodelling
Frédéric BARD • Marseille
- 10:05 Decoding the plasticity of stroma during pancreatic cancer progression and chemoresistance
Corinne BOUSQUET • Toulouse
- 10:25 Stromal influence on pancreatic cancer; Highlight on immune tolerance
Richard TOMASINI • Marseille
- 10:45 – 11:15 Coffee break
- 11:15 – 12:00** **EARLY DETECTION AND DIAGNOSIS**
Chaired by Luca MAZZARELLA • Milan, Italy
and Fabien CALVO • Paris, France
- 11:15 Morphomolecular heterogeneity of pancreatic intraductal papillary mucinous neoplasms
Jérôme CROS • Clichy
- 11:35 PANLIPSY: Integrating Multimodal Liquid Biopsies and AI to Define Early Detection Signatures in Pancreatic Ductal Adenocarcinoma
Catherine ALIX-PANABIÈRES • Montpellier
- 12:00 – 14:00** Lunch break and **POSTER SESSION**



14:00 – 14:20

EARLY ONSET AND RISK FACTORS

Chaired by Fabien CALVO • Paris

Young Onset Digestive adenocarcinoma,
a multicentric cohort study

Alice BOILÈVE • Villejuif

14:20 – 16:10

NEW TARGETS AND NEW TREATMENTS

Chaired by Olivier PEULEN • Liège, Belgium

and Rainer HEUCHEL • Stockholm, Sweden

14:20

New KRAS inhibitors

Pascal HAMMEL • Villejuif

14:40

Chemical control of cell adaptation

Raphaël RODRIGUEZ • Paris

15:00 – 15:30

Coffee break

15:30

Targeting netrin-1 in first-line patients with locally advanced
pancreatic cancer: from the idea to clinical data

Patrick MEHLEN • Lyon

15:50

Study of tumour heterogeneity and personalisation of pancreatic
cancer treatments

Nelson DUSETTI • Marseille

16:10

PRODIGE 104 A (FFCD 2307) – NEOPREDICT: A Phase II trial
using transcriptomic signatures to personalize neoadjuvant
chemotherapy for patients with resectable borderline
pancreatic adenocarcinoma

Brice CHANEZ • Marseille

16:30 – 16:45

CLOSING SESSION

Éric SOLARY • Vice President of Fondation ARC